Thrombosis

2007 ◽  
pp. 511-514
Keyword(s):  
Venous Thrombosis ◽  
Pulmonary Embolus ◽  
Major Complication ◽  
Central Venous Catheters ◽  
Thromboembolic Disease ◽  
Venous Thromboembolic Disease ◽  
Profound Impact ◽  
Patients With Cancer ◽  
Venous Thromboembolic

Venous thrombosis 512 Venous thromboembolic disease (VTE) includes thrombosis of superficial and deep veins (DVT), usually of the leg, thigh, and pelvis, pulmonary embolus (PE) and thrombosis associated with central venous catheters (CVCs). Venous thrombosis can have a profound impact on a cancer patient's quality of life. It is a well recognized, major complication of cancer and the second leading cause of death in hospitalized patients with cancer. It remains an under-diagnosed and under-treated condition....

Costs and outcomes associated with hospitalizations for venous thromboembolic disease in patients with malignant neoplasm

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 6590-6590
Author(s):  
S. Weidner ◽  
M. B. Schilling ◽  
C. Parks
Keyword(s):  
Malignant Neoplasm ◽  
Thromboembolic Disease ◽  
Cost Of Care ◽  
Cost Driver ◽  
Venous Thromboembolic Disease ◽  
Healthcare Database ◽  
Patients With Cancer ◽  
Increased Risk ◽  
Venous Thromboembolic ◽  
The Cost

6590 Background: Venous thromboembolic disease (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE) is a common occurrence in oncology, as patients with cancer have a greatly increased risk of VTE. Costs of VTE treatment are significant, including direct costs (expenditures for procedures, tests, medications, and services), indirect morbidity costs (lost income from work due to the condition or disability), and indirect mortality costs (lost income due to early mortality). Costs associated with VTE contribute to the overall cost of cancer care, however studies that examine the cost of care for oncology patients that develop VTEs are limited. Methods: A retrospective cohort study identified patients with cancer hospitalized during January 2006 through May 2008 using a large US healthcare database (>342 inpatient facilities across all US regions, ∼ 11 million patients and > 300 million charge- detail records). Patients with an ICD-9-CM code for malignant neoplasm (140.xx-208.xx) in combination with DVT or PE (415.11,415.19, 453.4,453.41,453.42) were included. Using Aspen's charge cost model, the hospital's clinical, utilization and billing, and cost accounting records healthcare cost, LOS, and mortality rates associated with these hospitalizations were calculated. Results: Data from 74 facilities with a mean bed size of 349 was utilized. A total of 77% of these facilities were not classified as teaching hospitals. Overall 1136 inpatients were identified with a diagnosis of malignant neoplasm and either DVT or PE. Table 1 shows the results. Conclusions: DVT/PE contributes to the cost of cancer treatment and is a considerable cost driver. Additionally, human costs are high. Aggressive practices to prevent these complications can result in a lower healthcare burden. In an era of restricted resources and value based purchasing, these data can be used to prioritize resource utilization. [Table: see text] [Table: see text]

A Multicenter Randomized Double-blind Study of Enoxaparin Compared with Unfractionated Heparin in the Prevention of Venous Thromboembolic Disease in Elderly In-patients Bedridden for an Acute Medical Illness

1996 ◽  
Vol 76 (04) ◽  
pp. 529-534 ◽  
Author(s):  
Jean-Fraçois Bergmann ◽  
Eric Neuhart
Keyword(s):  
Pulmonary Embolism ◽  
Venous Thrombosis ◽  
Thromboembolic Disease ◽  
Medical Illness ◽  
Double Blind Study ◽  
Venous Thromboembolic Disease ◽  
Double Blind ◽  
Once Daily ◽  
Venous Thromboembolic ◽  
Group 2

SummaryA multicenter, randomized double-blind study compared in two parallel groups the efficacy and safety of a low molecular weight heparin (LMWH) enoxaparin 20 mg once daily, with unfractionated heparin (UFH) 5000 IU twice daily, administered subcutaneously for 10 days, in the prevention of venous thrombosis disease in 442 hospitalized elderly patients bedridden for an acute medical illness. The main efficacy endpoint was defined as the occurrence of venous thrombosis, diagnosed by a daily fibrinogen uptake test, and/or documented clinical pulmonary embolism.Intention-to-treat analysis of efficacy showed that the incidence of venous thromboembolic events was low: 4.8% (10/207) in the LMWH group (9 episodes of isotopic venous thrombosis and one of scintigraphic pulmonary embolism), and 4.6% (10/216) in the UFH group (10 episodes of isotopic venous thrombosis). The two treatments were equivalent, where equivalence was defined as a maximum difference of 7% between the two groups (p = 0.0005).There were no significant differences in terms of safety between the 216 patients in the LMWH group and the 223 patients in the UFH group who received at least one injection of the randomized treatment. During the study period, 15 patients (3.4%) died (7 in the LMWH group and 8 in the UFH group): 2 sudden deaths, one in each group, including one case in which pulmonary embolism could not be excluded since no autopsy was performed, and 13 others deaths unrelated to the study treatments. Six patients (1.4%) presented a bleeding complication: 2 (0.9%) in the enoxaparin group (one major and one minor hemorrhage), and 4 (1.8%) in the UFH group (2 major and 2 minor hemorrhages).These results indicate that subcutaneous enoxaparin 20 mg once daily for 10 days is as effective and well tolerated as subcutaneous UFH 5000 IU twice daily in the prevention of venous thromboembolic disease in bedridden elderly in-patients presenting an acute medical illness.

Monitoring Heparin Therapy: Relationships between the Activated Partial Thromboplastin Time and Heparin Assays Based on Ex-Vivo Heparin Samples

1990 ◽  
Vol 63 (01) ◽  
pp. 016-023 ◽  
Author(s):  
A M H P van den Bessekaar ◽  
J Meeuwisse-Braun ◽  
R M Bertina
Keyword(s):  
Partial Thromboplastin Time ◽  
Plasma Sample ◽  
Ex Vivo ◽  
Correlation Coefficients ◽  
Heparin Therapy ◽  
Thromboembolic Disease ◽  
Activated Partial Thromboplastin Time ◽  
Venous Thromboembolic Disease ◽  
Venous Thromboembolic

SummaryFive different APTT reagents, two amidolytic anti-ITa assays, one amidoiytic anti-Xa assay, and one coagulometric anti-Xa/ anti-IIa assay were used to assess the effect of heparin in patients treated for venous thromboembolic disease. Good correlations were observed between lug-transformed APYE> determined with the various reagents (correlation coefficients: 0.92-0.96).Nevertheless there were important differences in the slopes of the lines of relationship between the APTT reagents.Good correlations were observed between the anti-Xa and anti-IIa assay results (correlation coefficients: 0.92-0.97). However, the amidolytic anti-Xa activity was significantly higher (p <0.001) than the two amidolytic anti-IIa activities. Less good correlations were observed between the log-transformed APTTs and the anti-Xa or anti-IIa activities (correlation coefficients: 0.64-0.78). The correlations were improved by transforming the APTT into APTT-ratio, i.e. the ratio of the patient’s APTT to the same patient’s APTT after removal of heparin from the plasma sample by means of ECTEOLA-cellulose treatment. The correlation coefficients of log (AFTT-ratio) with anti-Xa or anti-IIa ranged from 0.76 to 0.87.For both APTT and amidolytic heparin assay, the response to in vitro heparin was different from the response to ex vivo heparin.Therefore, equivalent therapeutic ranges should be assessed by using ex vivo samples rather than in vitro heparin. Because of the response differences between the APTT reagents, it is not adequate to define a therapeutic range for heparin therapy without specification of the reagent.

Periodontitis as A Risk Factor of Unprovoked Venous Thromboembolic Disease: An Emerging Association

2018 ◽  
Vol 2 (12) ◽  
Author(s):  
Nifosì Lorenzo ◽  
Zuccarello Mariateresa ◽  
Nifosì Antonio Fabrizio ◽  
Hervas Saus Vanessa ◽  
Nifosì Gianfilippo
Keyword(s):  
Risk Factor ◽  
Thromboembolic Disease ◽  
Venous Thromboembolic Disease ◽  
Venous Thromboembolic
Sign in / Sign up

Export Citation Format

Share Document